Advertisement

Immunoprophylaxis and Immunotherapy of Gram-negative Bacterial Infections

  • J. D. Baumgartner
  • M. P. Glauser
Part of the Immunology and Medicine Series book series (IMME, volume 25)

Abstract

Over the last decades the incidence of gram-negative bacterial infections has risen markedly in most medical centres1,2. At the Boston City Hospital, the incidence of gram-negative bacteraemia increased from 0.9/1000 admissions in 1935 to 11.2/1000 admissions in 19723. In the USA it was estimated that approximately 71 000 episodes of documented gram-negative septicaemia occurred annually, and an unknown, perhaps even higher, number of potentially lethal gram-negative infections occurred in the presence of sterile blood cultures4. During the last decade, the rise seems to have plateaued. At the present time, half of all cases of sepsis and septic shock are due to endotoxin-containing micro-organisms, the rest occur during gram-positive bacterial infections, and infrequently during fungal and even viral infections. Overall, despite adequate treatment of infection and supportive care in intensive care unit, sepsis kills an estimated 100 000 people a year in the United States5. The mortality associated with gram-negative bacteraemias is still in the range 20–35%3,4,6–9, and 50% or more of those developing gram-negative septic shock (20–30% of patients with gram-negative bacteremia) die10–13. The development of a new effective treatment is thus a major challenge of modern medicine.

Keywords

Septic Shock Intravenous Immune Globulin IVIG Preparation Monoelonal Antibody Rough Mutant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kreger BE, Craven DE, Carling PC, et al. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med. 1980; 68: 332–343.PubMedCrossRefGoogle Scholar
  2. 2.
    McCabe MR, Jackson GG. Gram-negative bacteremia I. Etiology and ecology. Arch Intern Med. 1962; 110: 845–343.Google Scholar
  3. 3.
    McGowan JE Jr, Barnes MW, Finland M. Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935–1972) with special reference to hospital-acquired cases. J Infect Dis. 1975; 132: 326–341.CrossRefGoogle Scholar
  4. 4.
    Wolff SD, Bennett JV. Gram-negative-rod bacteremia. N Engl J Med. 1974; 291: 733–734.PubMedCrossRefGoogle Scholar
  5. 5.
    Increase in National Hospital Discharge Survey rates for septicemia–United States, 1979–1987. MMWR. 1990; 39; 31–34.Google Scholar
  6. 6.
    Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983; 5: 629–638.PubMedCrossRefGoogle Scholar
  7. 7.
    Felty AR, Keefer CS. Bacillus coli sepsis. A clinical study of 28 cases of bloodstream infection by the colon bacillus. JAMA. 1924; 82: 1430–1433.CrossRefGoogle Scholar
  8. 8.
    Kreger BE, Craven DE, Carling PC, et al. Gram-negative bacteremia. IV. Reevaluation of clinical features and treatment in 612 patients. Am J Med. 1980; 68: 344–355.PubMedCrossRefGoogle Scholar
  9. 9.
    Shenep JL, Morgan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1984; 150: 380–388.PubMedCrossRefGoogle Scholar
  10. 10.
    Bone RG, Fisher CJ, Clemmer TP. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987; 317: 653–658.PubMedCrossRefGoogle Scholar
  11. 11.
    Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med. 1984; 311: 1137–1143.PubMedCrossRefGoogle Scholar
  12. 12.
    The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987; 317: 659–665.CrossRefGoogle Scholar
  13. 13.
    Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982; 307: 1225–1230.PubMedCrossRefGoogle Scholar
  14. 14.
    Glauser MP, Zanetti G, Baumgartner JD, et al. Septic shock: pathogenesis. Lancet. 1991; 338: 732–736.PubMedCrossRefGoogle Scholar
  15. 15.
    Jacob L. Ueber allgemain Infektion durch Bacterium coli commune. DAKMM. 1909; 97: 303–307.Google Scholar
  16. 16.
    De Maria A, Craven DE, Heffernan JJ, et al. Naloxone versus placebo in treatment of septic shock. Lancet. 1985; i: 1363–1365.Google Scholar
  17. 17.
    Wolff SM. Biological effects of bacterial endotoxins in man. J Infect Dis. 1973; 128: 259S - 264S.CrossRefGoogle Scholar
  18. 18.
    Fuller NA, Wu MC, Wilkinson RG, et al. The biosynthesis of cell wall lipopolysaccharide in Escherichia coli. VII. Characterization of heterogenous `core’ oligosaccharide structures. J Biol Chem. 1973; 248: 7938–7950.PubMedGoogle Scholar
  19. 19.
    Jansson PE, Lindberg AA, Lindberg B, et al. Structural studies on the hexose region of the core in lipopolysaccharides from enterobacteraceae. Eur J Biochem. 1981; 115: 571–577.PubMedCrossRefGoogle Scholar
  20. 20.
    Pollack M, Chia JKS, Koles NL, et al. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis. 1989; 159: 168–188.PubMedCrossRefGoogle Scholar
  21. 21.
    Rietschel ET, Wollenweber HW, Brade H, et al. Structure and conformation of the lipid A component of lipopolysaccharides. In: Proctor RA, Rietschel ET, eds. Handbook of endotoxin. Volume 1: Chemistry of endotoxin. Amsterdam: Elsevier, 1984: 187–220.Google Scholar
  22. 22.
    Pfeiffer R, Kolle W. Ueber di spezifische Immunitaets-reaktion der Typhus-bacillen. Z Hyg Infektionskr. 1896; 21: 203–246.CrossRefGoogle Scholar
  23. 23.
    Tate WJ, Douglas H, Braude AI. Protection against lethality of E. coli endotoxin with `O’ antiserum. Ann NY Acad Sci. 1966; 133: 746–762.PubMedCrossRefGoogle Scholar
  24. 24.
    Baker CJ, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med. 1992; 327: 213–219.PubMedCrossRefGoogle Scholar
  25. 25.
    Chirico G, Rondini G, Piebani S, et al. Intravenous immunoglobulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr. 1987; 110: 437–442.PubMedCrossRefGoogle Scholar
  26. 26.
    Glinz W, Grob JP, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients with multiple trauma. Intensive Care Med. 1985; 11: 288–294.PubMedCrossRefGoogle Scholar
  27. 27.
    Hague KN, Zaidi MH, Hague SK, et al. Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants. Pediatr Infect Dis. 1986; 5: 622–625.CrossRefGoogle Scholar
  28. 28.
    The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med. 1992; 327: 234–240.CrossRefGoogle Scholar
  29. 29.
    Dominioni L, Dionigi R, Zanello M, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg. 1991; 126: 236–240.PubMedCrossRefGoogle Scholar
  30. 30.
    Duswald KH, Müller K, Seifert J, et al. Wirksamkeit von i.v. Gammaglobulin gegen backterielle Infektionen chirurgischer Patienten. Muench Med Wschr. 1980; 122: 832–836.Google Scholar
  31. 31.
    Just HM, Metzger M, Vogel W, et al. Einfluss einter adjuvanten immunoglobulintherapie auf Infectionen bei Patienten einer opertiven Intensive-Therapie-Station. Klin Wochenschr. 1986; 64: 245–256.PubMedCrossRefGoogle Scholar
  32. 33.
    Sidiropoulos D, Böhme U, Von Murait G, et al. Immunoglobulinsubstitution bei der Behandlung der neonatalen Sepsis. Schweiz Med Wochenschr. 1981; 111: 1649–1655.PubMedGoogle Scholar
  33. 34.
    Zanetti G, Glauser MP, Baumgartner JD. Use of immunoglobulins in prevention and treatment of infections in critically-ill patients: review and critique. Rev Infect Dis. 1991; 13: 985–992.PubMedCrossRefGoogle Scholar
  34. 35.
    Young LS. Immunoprophylaxis and serotherapy of bacterial infections. Am J Med. 1984; 76: 664–671.PubMedCrossRefGoogle Scholar
  35. 36.
    Baumgartner JD, Glauser MP. Controversies in the passive immunotherapy of bacterial infections in the critically-ill patients. Rev Infect Dis. 1987; 9: 194–205.PubMedCrossRefGoogle Scholar
  36. 37.
    Collins MS, Dorsey JH. Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulins G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo. Am J Med. 1984; 76: 155–160.PubMedCrossRefGoogle Scholar
  37. 38.
    Collins MS, Roby RE. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med. 1984; 76: 168–174.PubMedCrossRefGoogle Scholar
  38. 39.
    Holder IA, Naglich JG. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin. Am J Med. 1984; 76: 161–167.PubMedCrossRefGoogle Scholar
  39. 40.
    Pennington JE, Menkes E. Type-specific versus cross-protective vaccination for gram-negative pneumonia. J Infect Dis. 1981; 144: 599–603.PubMedCrossRefGoogle Scholar
  40. 41.
    Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983; 147: 1090–1098.PubMedCrossRefGoogle Scholar
  41. 42.
    Pennington JE. Impact of molecular biology on Pseudomonas aeruginosa immunization. J Hosp Infect. 1988; 11 (Suppl.): 96–102.PubMedCrossRefGoogle Scholar
  42. 43.
    Westphal O, Jann K, Himmelspach K. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog Allergy. 1983; 33: 9–39.PubMedGoogle Scholar
  43. 44.
    Nixdorff KK, Schlecht SS. Heterogeneity of the haemagglutinin responses to Salmonella minnesota R-antigens in rabbits. J Gen Microbiol. 1972; 71: 425–440.PubMedCrossRefGoogle Scholar
  44. 45.
    Heumann D, Baumgartner JD, Jacot-Guillarmod H, et al. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides. J Infect Dis. 1991; 163: 762–768.PubMedCrossRefGoogle Scholar
  45. 46.
    Braude AI, Douglas H. Passive immunization against the local Schwartzman reaction. J Immunol. 1972; 108: 505–512.PubMedGoogle Scholar
  46. 47.
    Chedid L, Parant M, Parant F, et al. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol. 1968; 100: 292–301.PubMedGoogle Scholar
  47. 48.
    McCabe WR. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol. 1972; 108: 601–610.PubMedGoogle Scholar
  48. 49.
    Pollack M, Huang AI, Prescott RK, et al. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983; 72: 1874–1881.PubMedCrossRefGoogle Scholar
  49. 50.
    Pollack M, Young LS. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicaemia in man J Clin Invest. 1979; 63: 276–286.PubMedCrossRefGoogle Scholar
  50. 51.
    Zinner SH, McCabe WR. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis. 1976; 133: 37–45.PubMedCrossRefGoogle Scholar
  51. 52.
    Baumgartner JD, Glauser MP, McCutchan JA, et al. Prevention of Gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet. 1985; ii: 59–63.CrossRefGoogle Scholar
  52. 53.
    Eskenazy M, Konstantinov G, Ivanova R, et al. Detection by immunofluorescence of common antigenic determinants in unrelated Gram-negative bacteria and their lipopolysaccharides. J Infect Dis. 1977; 135: 965–969.PubMedCrossRefGoogle Scholar
  53. 54.
    Young LS, Hoffman KR, Stevens P. Core glycolipid of enterobacteriaceae: immunofluorescent detection of antigen and antibody. Proc Soc Biol Med. 1975; 149: 389–396.Google Scholar
  54. 55.
    Baumgartner JD, O’Brien TX, Kirkland TN, et al. Demonstration of cross-reactive antibodies to smooth Gram-negative bacteria in Escherichia coli J5 antiserum. J Infect Dis. 1987; 156: 136–143.PubMedCrossRefGoogle Scholar
  55. 56.
    Overbeck BP, Schellekens JFP, Lippe W, et al. Carumonam enhances reactivity of Escherichia coli with mono-and polyclonal antisera to rough mutant Escherichia coli J5. J Clin Microbiol. 1987; 156: 136–143.Google Scholar
  56. 57.
    McCallus DE, Norcross NL. Antibody specific for Escherichia coli J5 crossreacts to various degrees with an Escherichia coli clinical isolates grown for different lengths of time. Infect Immun. 1987; 55: 1042–1046.PubMedGoogle Scholar
  57. 58.
    De Jongh-Leuvenik J, Vreede RW, Marcelis JH, et al. Detection of antibodies against lipopolysaccharides of Escherichia coli and Salmonella R and S strains by immunoblotting. Infect Immun 1985; 50: 716–720.Google Scholar
  58. 59.
    Johns MA, Bruins SC, McCabe WR Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants. Infect Immun. 1977; 17: 9–15.PubMedGoogle Scholar
  59. 60.
    Ng AK, Chen CLH, Chang CM, et al. Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some Gram-negative infections. J Gen Microbiol. 1976; 94: 107–116.PubMedCrossRefGoogle Scholar
  60. 61.
    Schwartzer TA, Alcid DV, Numsuwan V, et al. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4. J Infect Dis. 1989; 159: 35–42.PubMedCrossRefGoogle Scholar
  61. 62.
    Siber GR, Kania SA, Warren HS. Cross-reactivity of rabbit antibodies to lipopolysaccharide of Escherichia coli and other gram-negative bacteria. J Infect Dis. 1985; 152: 954–964.PubMedCrossRefGoogle Scholar
  62. 63.
    Bogard WC Jr, Dunn DL, Abernethy K, et al. Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity. Infect Immun 1986; 55: 899–908.Google Scholar
  63. 64.
    Dunn DL, Bogard WC Jr, Cerra FB. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surgery. 1985; 98: 283–289.PubMedGoogle Scholar
  64. 65.
    Kirkland TN, Colwell DE, Michalek SM, et al. Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies. J Immunol. 1986; 137: 3614–3619.PubMedGoogle Scholar
  65. 66.
    Miner KM, Manyak CL, Williams E. Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immun. 1986; 52: 56–62.PubMedGoogle Scholar
  66. 67.
    Mutharia LM, Crockford G, Bogard WC Jr, et al. Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species. Infect Immun. 1984; 45: 631–636.PubMedGoogle Scholar
  67. 68.
    Nelles MJ, Niswander CA. Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of Gram-negative bacteria. Infect Immun. 1984; 46: 677–681.PubMedGoogle Scholar
  68. 69.
    Gigliotti F, Shenep JL. Failure of monoclonal antibodies to core glycolipid to bind intact strains of Escherichia coli. J Infect Dis. 1985; 151: 1005–1011.PubMedCrossRefGoogle Scholar
  69. 70.
    Pollack M, Raubitschek AA, Larrick JW. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region lipopolysaccharides. J Clin Invest. 1987; 79: 1421–1430.PubMedCrossRefGoogle Scholar
  70. 71.
    Shenep JL, Gigliotti F, Davis DS, et al. Reactivity of antibodies to core glycolipid with gram-negative bacteria. Rev Infect Dis. 198 7; 9(Suppl.): S639–S643.Google Scholar
  71. 72.
    Young LS, Stevens P. Cross-protective immunity to gram-negative bacilli: studies with core glycolipid of Salmonella minnesota and antigens of Streptococcus pneumoniae. J Infect Dis. 1977; 136: 174S - 180S.CrossRefGoogle Scholar
  72. 73.
    Young LS, Stevens P, Ingram J. Functional role of antibody against `core’ glycolipid of enterobacteriaceae. J Clin Invest. 1975; 56: 850–861.PubMedCrossRefGoogle Scholar
  73. 74.
    Ziegler EJ, Douglas H, Sherman JE, et al. Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. J Immunol. 1973; 111: 433–438.PubMedGoogle Scholar
  74. 75.
    Michael JG, Mallah I. Immune response to parental and rough mutant strains of Salmonella minnesota. Infect Immun. 1981; 33: 784–787.PubMedGoogle Scholar
  75. 76.
    Baumgartner JD, Glauser MP. Immunotherapy of endotoxemia and septicemia. Immunobiology. 1993; 187: 464–477.PubMedCrossRefGoogle Scholar
  76. 77.
    Baumgartner JD, Wu MM, Glauser MP. Interpretation of data regarding the protection afforded by serum, IgG or IgM antibodies after immunization with the rough mutant R595 of Salmonella minnesota. J Infect Dis. 1989; 160: 347–348.PubMedCrossRefGoogle Scholar
  77. 78.
    Calandra T, Glauser MP, Schellekens J, et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double blind, randomized study. J Infect Dis. 1988; 158: 312–319.PubMedCrossRefGoogle Scholar
  78. 79.
    McCabe WR, DeMaria A Jr, Berberich H, et al. Immunization with rough mutants of Salmonella minnesota: Protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis. 1988; 158: 291–300.PubMedCrossRefGoogle Scholar
  79. 80.
    Greisman SE. Experimental gram-negative bacterial sepsis: optimal methylprednisolone requirements for prevention of mortality not preventable by antibiotics alone. Proc Soc Biol Med. 1982; 170: 436–442.Google Scholar
  80. 81.
    Greisman SE, Johnston CA. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. J Infect Dis. 1987; 157: 54–64.CrossRefGoogle Scholar
  81. 82.
    Hodgin LA, Drews J. Effect of active and passive immunizations with lipid A and Salmonella minnesota Re 595 on gram-negative infections in mice. Infection. 1976; 4: 5–10.PubMedCrossRefGoogle Scholar
  82. 83.
    Martinez D, Callahan LT III. Prophylaxis of Pseudomonas aeruginosa infections in leukopenia mice by a combination of active and passive immunization. Eur J Clin Microbiol. 1985; 4: 186–189.PubMedCrossRefGoogle Scholar
  83. 84.
    Morris DD, Bottoms GD, Whitlock RH, et al. Endotoxin-induced changes in plasma concentrations of thromboxane and prostacyclin in neonatal calves given antiserum to a mutant Escherichia coli (J5). Am J Vet Res. 1986; 47: 2520–2524.PubMedGoogle Scholar
  84. 85.
    Morris DD, Cullor JS, Whitlock RH, et al. Endotoxemia in neonatal calves given an antiserum to a mutant Escherichia coli (J5). Am J Vet Res. 1986; 47: 2554–2565.PubMedGoogle Scholar
  85. 86.
    Morris DD, Whitlock RH, Merryman GS, et al. Endotoxin-induced changes in the hemostatic system in neonatal calves: the effect of antiserum to mutant Escherichia coli (J5). Am J Vet Res. 1986; 47: 2514–2519.PubMedGoogle Scholar
  86. 87.
    Mullan NA, Newsome PM, Cunnington PG, et al. Protection against gram-negative infections with antiserum to lipid A from Salmonella minnesota R595. Infect Immun. 1974; 10: 1195–1201.PubMedGoogle Scholar
  87. 88.
    Peter G, Chernow M, Keating MH, et al. Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia. Infection. 1982; 10: 228–232.PubMedCrossRefGoogle Scholar
  88. 89.
    Sadoff JC, Futrovsky SL, Sidberry HF, et al. Detoxified lipopolysaccharide-protein conjugates. Semin Infect Dis. 1982; 4: 346–354.Google Scholar
  89. 90.
    Straube E, Naumann G, Broschewitz U. Effect of immunization with Escherichia coli endotoxin with `O’ antiserum. Ann NY Acad Sci. 1966; 133: 746–762.CrossRefGoogle Scholar
  90. 91.
    Trautmann M, Hahn H. Antiserum against Escherichia coli J5: A re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria. Infection. 1985; 13: 140–145.PubMedCrossRefGoogle Scholar
  91. 92.
    Van Dick WC, Verbrugh HA, Van Erne-van der Tol ME, et al. Escherichia coli antibodies in opsonisation and protection against infection. J Med Microbiol. 1981; 14: 381–389.CrossRefGoogle Scholar
  92. 93.
    Vuopio-Varkila J. Experimental Escherichia coli peritonitis in immunosuppressed mice: the role of specific and non-specific immunity. J Med Microbiol. 1988; 25: 33–39.PubMedCrossRefGoogle Scholar
  93. 94.
    Vuopio-Varkila J, Karvonen M, Saxen H. Protective capacity of antibodies to outer-membrane components of Escherichia coli in a systemic mouse peritonitis model. J Med Microbiol. 1988; 25: 77–84.PubMedCrossRefGoogle Scholar
  94. 95.
    Weinbreck P, Baumgartner JD, Cometta A, et al. Failure of passive immunization with rabbit antiserum to E. coli J5 in bacteremia and endotoxemic lethality in mice. Abstract 622: in Programme and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles. Washington: American Society for Microbiology, 1988: 218.Google Scholar
  95. 96.
    Ziegler EJ. Protective antibody to endotoxin core: the emperor’s new clothes? J Infect Dis. 1988; 158: 286–290.PubMedCrossRefGoogle Scholar
  96. 97.
    Chong KT, Huston M. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram-negative sepsis. J Infect Dis. 1987; 156: 713–719.PubMedCrossRefGoogle Scholar
  97. 98.
    Urbaschek B, Ditter B, Becker KP, et al. Protective effects and role of endotoxin in experimental septicemia. Circ Shock. 1984; 14: 209–222.PubMedGoogle Scholar
  98. 99.
    Woods JP, Black JR, Barritt DS, et al. Resistance to meningococcemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection. Infect Immun 1987; 55: 1927–1928.PubMedGoogle Scholar
  99. 100.
    Silva AT, Appelmelk BJ, Cohen J. Purified monoclonal antibody to endotoxin core fails to protect mice from experimental gram-negative sepsis. J Infect Dis. 1993; 168: 256–257.PubMedCrossRefGoogle Scholar
  100. 101.
    McCabe WR, Kreger BE, Johns M. Type-specific and cross-reactive antibodies in gramnegative bacteremia. N Engl J Med. 1972; 287: 261–267.PubMedCrossRefGoogle Scholar
  101. 102.
    Baumgartner JD, Heumann D, Calandra T, et al. Antibodies to core LPS in patients with Gram-negative septic shock: Absence of correlation with outcome. In: Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Washington: American Society for Microbiology, 1989: 175.Google Scholar
  102. 103.
    J5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study. J Infect Dis. 1992; 165: 695–701.CrossRefGoogle Scholar
  103. 104.
    McCutchan JA, Wolf JL, Ziegler EJ, et al. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweiz Med Wschr. 1983; 113 (Suppl. 14): 40–45.Google Scholar
  104. 105.
    Davis CE, Ziegler EJ, Arnold K. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med. 1978; 147: 1007–1017.PubMedCrossRefGoogle Scholar
  105. 106.
    Baumgartner JD, Heumann D, Calandra T, et al. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. J Infect Dis. 1991; 163: 769–772.PubMedCrossRefGoogle Scholar
  106. 107.
    Baumgartner JD. Immunotherapy with antibodies to core LPS: a critical appraisal. Infect Dis Clin North Am. 1991; 5: 915–927.PubMedGoogle Scholar
  107. 108.
    Bruins SC, Stumacher R, Johns MA, et al. Immunization with R mutants of Salmonella minnesota. III. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immun. 1977; 17: 16–20.PubMedGoogle Scholar
  108. 109.
    Galanos C, Luederitz O, Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem. 1971; 24: 116–122.PubMedCrossRefGoogle Scholar
  109. 110.
    Mattsby-Baltzer I, Kaijser B. Lipid A and anti-lipid A. Infect Immun 1979; 23: 758–763.PubMedGoogle Scholar
  110. 111.
    Teng NNH, Kaplan HS, Hebert JM. Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA. 1985; 82: 1790–1794.PubMedCrossRefGoogle Scholar
  111. 112.
    Young LS, Gascon R, Alam S, et al. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis. 1989; 11 (Suppl.7): S1564 - S1571.PubMedCrossRefGoogle Scholar
  112. 113.
    Baumgartner JD, Heumann D, Glauser MP. The HA-1A monoclonal antibody for gram-negative sepsis. N Engl J Med. 1991; 325: 281–282.Google Scholar
  113. 114.
    Baumgartner JD, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor a and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med. 1990; 171: 889–896.PubMedCrossRefGoogle Scholar
  114. 115.
    Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991; 324: 429–436.PubMedCrossRefGoogle Scholar
  115. 116.
    Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med. 1992; 326: 1153–1157.PubMedCrossRefGoogle Scholar
  116. 117.
    Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991; 266: 1097–1102.PubMedCrossRefGoogle Scholar
  117. 118.
    Wenzel R, Bone R, Fein A, et al. Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody ES in gram-negative sepsis. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1991: 234.Google Scholar
  118. 119.
    Winslow R. Effectiveness of new drug against septic infections is questioned by agency. Wall Street Journal, 1992; Apr 16: B5.Google Scholar
  119. 120.
    Fisher LM. Investors punish Centocor for more bad news. New York Times. 1993; Jan 19: Dl.Google Scholar
  120. 121.
    Zanetti G, Heumann D, Gerain J, et al. Cytokine production after intravenous or peritoneal gram negative bacterial challenge in mice. Comparative protective efficacy of antibodies to TNFa and to LPS. J Immunol. 1992; 148: 1890–1897.PubMedGoogle Scholar
  121. 122.
    Piercey L. Star-crossed lovers–is biotech bad for science? Biopeople. 1993; 4: 20–27.Google Scholar
  122. 123.
    Di Padova FE, Barclay R, Liehl E, et al. Widely cross-reactive anti-LPS core monoclonal antibodies have LPS neutralizing properties. Abstract CB404. J Cell Biochem. 1992: Suppl. 16C: 170.Google Scholar
  123. 124.
    Saxen H, Vuopio-Varkila J, Luk J, et al. Detection of enterobacterial lipopolysaccharides and experimental endotoxemia by means of an immunolimulus assay using both serotypespecific and cross-reactive antibodies. J Infect Dis. 1993; 168: 393–399.PubMedCrossRefGoogle Scholar
  124. 125.
    Heumann D, Gallay P, Betz-Corradin S, et al. Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. J Infect Dis. 1993; 167: 1351–1357.PubMedCrossRefGoogle Scholar
  125. 126.
    Marra MN, Snable JL, Scott RW, et al. Bactericidal/permeability-increasing protein: a naturally occurring lipopolysaccharide antagonist. Circ Shock. 1991; 34: 47.Google Scholar
  126. 127.
    Ooi CE, Weiss J, Doerfler ME, et al. Endotoxin-neutralizing properties of the 24 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55–60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med. 1991; 174: 649–655.PubMedCrossRefGoogle Scholar
  127. 128.
    Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990; 249: 1429–1431.PubMedCrossRefGoogle Scholar
  128. 129.
    Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem. 1988; 263: 13479–13481.PubMedGoogle Scholar
  129. 130.
    Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986; 164: 777–793.PubMedCrossRefGoogle Scholar
  130. 131.
    Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990; 249: 1431–1433.PubMedCrossRefGoogle Scholar
  131. 132.
    Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991; 147: 1567–1574.PubMedGoogle Scholar
  132. 133.
    Heumann D, Gallay P, Barras C, et al. Control of LPS binding and LPS-induced TNF secretion in human peripheral blood monocytes. J Immunol. 1992; 148: 3505–3512.PubMedGoogle Scholar
  133. 134.
    Greisman SE, DuBuy JB, Woodward CL. Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice. Proc Soc Biol Med. 1978; 158: 482–490.Google Scholar
  134. 135.
    Greisman SE, DuBuy JB, Woodward CL. Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun. 1979; 25: 538–557.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • J. D. Baumgartner
  • M. P. Glauser

There are no affiliations available

Personalised recommendations